Progress in Schizophrenia Research and Treatment
This section contains a compilation of recent publications that have shaped the thinking in the field as well as classic works that remain important to the subject reviewed in this issue. This bibliography has been compiled by experts in the field and members of the editorial and advisory boards. Entries are listed chronologically and within topics and years by first author. Articles from the bibliography that are reprinted in this issue are in bold type.
2020
Keepers G, Fochtmann L, Anzia J, et al: Guideline Writing Group. The American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia. 2020 American Psychiatric Association. https://www.psychiatry.org/psychiatrists/practice/clinical-practice-guidelines
Taipale H, Lähteenvuo M, Tanskanen A, et al: Comparative effectiveness of antipsychotics for risk of attempted or completed suicide among persons with schizophrenia. Schizophr Bull, in press
Bowie CR, Bell MD, Fiszdon JM, et al: Cognitive remediation for schizophrenia: an expert working group white paper on core techniques. Schizophr Res 2020; 215:49–53
Goldsmith DR, Rapaport MH: Inflammation and negative symptoms of schizophrenia: implications for reward processing and motivational deficits. Front Psychiatry 2020; 11:46
Ostuzzi G, Papola D, Gastaldon C, et al: Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations. BMC Med 2020; 18:215
Potkin SG, Kane JM, Correll CU, et al: The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. NPJ Schizophr 2020; 6:1
2019
Buchanan A, Sint K, Swanson J, et al: Correlates of future violence in people being treated for schizophrenia. Am J Psychiatry 2019; 176:694–701
Cella M, Wykes T: The nuts and bolts of cognitive remediation: exploring how different training components relate to cognitive and functional gains. Schizophr Res 2019; 203:12–16
Faden J, Citrome L: Resistance is not futile: treatment-refractory schizophrenia—overview, evaluation and treatment. Expert Opin Pharmacother 2019; 20:11–24
Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al: Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. (published correction appears in Lancet. 2019 Sep 14;394(10202:918) Lancet 2019; 394:939–951
Iasevoli F, De Luca V, Nucifora FC: Editorial: neurobiology, clinical course, and therapeutic approaches of treatment-resistant schizophrenia: toward an integrated view. Front Psychiatry 2019; 10:870
Lean M, Fornells-Ambrojo M, Milton A, et al: Self-management interventions for people with severe mental illness: systematic review and meta-analysis. Br J Psychiatry 2019; 214:260–268
Marder SR, Cannon TD: Schizophrenia. N Engl J Med 2019; 381:1753–1761
Roerig JL: Clozapine augmentation strategies. Ment Health Clin 2019; 9:336–348
Smith RC, Leucht S, Davis JM: Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis. Psychopharmacology (Berl) 2019; 236:545–559
Tiihonen J, Taipale H, Mehtälä J, et al: Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry 2019; 76:499–507
2018
Cassidy RM, Yang F, Kapczinski F, et al: Risk factors for suicidality in patients with schizophrenia: a systematic review, meta-analysis, and meta-regression of 96 studies. Schizophr Bull 2018; 44:787–797
Dondé C, Vignaud P, Poulet E, et al: Management of depression in patients with schizophrenia spectrum disorders: a critical review of international guidelines. Acta Psychiatr Scand 2018; 138:289–299
Girgis RR, Ciarleglio A, Choo T, et al: A randomized, double-blind, placebo-controlled clinical trial of tocilizuamb, an interleukin-6 receptor antibody, for residual symptoms in schizophrenia. Neuropsychopharmacology 2018; 43:1317–1323
Harvey PD, McGurk SR, Mahncke H, et al: Controversies in computerized cognitive training. Biol Psychiatry Cogn Neurosci Neuroimaging 2018; 3:907–915
Ijaz S, Bolea B, Davies S, et al: Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews. BMC Psychiatry 2018; 18:275
Kesby JP, Eyles DW, McGrath JJ, et al: Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience. Transl Psychiatry 2018; 8:30
Krynicki CR, Upthegrove R, Deakin JFW, et al: The relationship between negative symptoms and depression in schizophrenia: a systematic review. Acta Psychiatr Scand 2018; 137:380–390
Pringsheim T, Gardner D, Addington D, et al: The assessment and treatment of antipsychotic-induced akathisia. Can J Psychiatry 2018; 63:719–729
Radua J, Ramella-Cravaro V, Ioannidis JPA, et al: What causes psychosis? An umbrella review of risk and protective factors. World Psychiatry 2018; 17:49–66
Taipale H, Mehtälä J, Tanskanen A, et al: Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia—a nationwide study with 20-year follow-up. Schizophr Bull 2018; 44:1381–1387
2017
Correll CU, Rubio JM, Inczedy-Farkas G, et al: Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry 2017; 74:675–684
Fusar-Poli P, McGorry PD, Kane JM: Improving outcomes of first-episode psychosis: an overview. World Psychiatry 2017; 16:251–265
Goff DC, Falkai P, Fleischhacker WW, et al: The long-term effects of antipsychotic medication on clinical course in schizophrenia. Am J Psychiatry 2017; 174:840–849
Howells FM, Kingdon DG, Baldwin DS: Current and potential pharmacological and psychosocial interventions for anxiety symptoms and disorders in patients with schizophrenia: structured review. Hum Psychopharmacol 2017; 32
Howes OD, McCutcheon R, Agid O, et al: Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry 2017; 174:216–229
Marder SR, Galderisi S: The current conceptualization of negative symptoms in schizophrenia. World Psychiatry 2017; 16:14–24
McDonagh MS, Dana T, Selph S, et al: Treatments for schizophrenia in adults: a systematic review. comparative effectiveness review no. 198. AHRQ pub no. 17(18)-EHC031-EF. Rockville, MD, Agency for Healthcare Research and Quality, Oct 2017. https://effectivehealthcare.ahrq.gov/topics/schizophrenia-adult/research-2017.
Miyaoka T, Wake R, Hashioka S, et al: Remission of psychosis in treatment-resistant schizophrenia following bone marrow transplantation: a case report. Front Psychiatry 2017; 8:174
Wimberley T, MacCabe JH, Laursen TM, et al: Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia. Am J Psychiatry 2017; 174:990–998
2016
Citrome L, McEvoy JP, Saklad SR: Guide to the management of clozapine-related tolerability and safety concerns. Clin Schizophr Relat Psychoses 2016; 10:163–177
Dixon LB, Holoshitz Y, Nossel I: Treatment engagement of individuals experiencing mental illness: review and update. World Psychiatry 2016; 15:13–20
Helfer B, Samara MT, Huhn M, et al: efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry 2016; 173:876–886
Miller BJ, Dias JK, Lemos HP, et al: An open-label, pilot trial of adjunctive tocilizumab in schizophrenia. J Clin Psychiatry 2016; 77:275–276
Sekar A, Bialas AR, de Rivera H, et al: Schizophrenia risk from complex variation of complement component 4. Nature 2016; 530:177–183
Stroup TS, Gerhard T, Crystal S, et al: Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia. Am J Psychiatry 2016; 173:166–173
Weiden PJ: Beyond psychopharmacology: emerging psychosocial interventions for core symptoms of schizophrenia. Focus 2016; 14:315–327
2015
Czobor P, Van Dorn RA, Citrome L, et al: Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies. Eur Neuropsychopharmacol 2015; 25:1158–1166
Najjar S, Pearlman DM: Neuroinflammation and white matter pathology in schizophrenia: systematic review. Schizophr Res 2015; 161:102–112
Petrides G, Malur C, Braga RJ, et al: Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. Am J Psychiatry 2015; 172:52–58
Sommer IE, van Bekkum DW, Klein H, et al: Severe chronic psychosis after allogeneic SCT from a schizophrenic sibling. Bone Marrow Transplant 2015; 50:153–154
Further Reading
Benros ME, Nielsen PR, Nordentoft M, et al: Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am J Psychiatry 2011; 168:1303–1310
Borgwardt SJ, Dickey C, Hulshoff Pol H, et al: Workshop on defining the significance of progressive brain change in schizophrenia: December 12, 2008 American College of Neuropsychopharmacology (ACNP) All-Day Satellite, Scottsdale, Arizona. The Rapporteurs’ Report. Schizophr Res 2009; 112:32–45
Brown AS, Derkits EJ: Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry 2010; 167:261–280
Burns AM, Erickson DH, Brenner CA: Cognitive-behavioral therapy for medication-resistant psychosis: a meta-analytic review. Psychiatr Serv 2014; 65:874–880
Cella M, Bishara AJ, Medin E, et al: Identifying cognitive remediation change through computational modelling--effects on reinforcement learning in schizophrenia. Schizophr Bull 2014; 40:1422–1432
Correll CU, Rummel-Kluge C, Corves C, et al: Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 2009; 35:443–457
Gallego JA, Nielsen J, De Hert M, et al: Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf 2012; 11:527–542
Howes OD, Murray RM: Schizophrenia: an integrated sociodevelopmental–cognitive model. Lancet 2014; 383:1677–1687
Sommer IE, van Westrhenen R, Begemann MJ, et al: Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull 2014; 40:181–191
Turner DT, van der Gaag M, Karyotaki E, et al: Psychological interventions for psychosis: a meta-analysis of comparative outcome studies. Am J Psychiatry 2014; 171:523–538
Whitfield-Gabrieli S, Thermenos HW, Milanovic S, et al: Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia. Proc Natl Acad Sci USA 2009; 106:1279–1284
Information & Authors
Information
Published In
History
Published in print: Fall 2020
Published online: 6 November 2020
Authors
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
There are no citations for this item
View Options
View options
PDF/ePub
View PDF/ePubGet Access
Login options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).